Chronic viral hepatitis is one of the common chronic infectious diseases in China, especially chronic hepatitis B, which seriously endangers people’s health. In order to further standardize the prevention, diagnosis and treatment of chronic viral hepatitis, the color-holding treatment of chronic hepatitis B is briefly described according to the principles of evidence-based medicine. The goals of treatment for chronic hepatitis B are: to maximize long-term suppression or clearance of hepatitis B virus, hepatitis C virus and hepatitis D virus, to reduce hepatocyte inflammation and necrosis and their resulting liver fibrosis, to delay the progression of the disease, to reduce the occurrence of cirrhosis, primary liver cancer and their complications, and thus to improve the quality of life, etc. Emphasis is placed on individualized treatment of chronic viral hepatitis, with a comprehensive assessment of the patient implemented prior to treatment, including condition, family history, treatment history, financial situation, compliance, etc. Attention is paid to correct and comprehensive responses to patient counseling before and after treatment. For the treatment of chronic hepatitis B, a comprehensive treatment plan is used according to the patient’s specific situation, including reasonable rest and nutrition, psychological balance, antiviral, regulation of body immunity, improvement and restoration of liver function, and anti-fibrosis. It is emphasized that antiviral is the key to treatment for chronic viral hepatitis. Currently has been officially approved by China’s Food and Drug Administration (SFDA) for chronic hepatitis B antiviral treatment drugs are the following six: common interferon alpha, long-acting interferon alpha, lamivudine, adefovir, entecavir, and telbivudine; using advanced treatment technologies at home and abroad, early viral response levels can be monitored in a timely manner to predict and optimize and change treatment regimens, and according to the treatment roadmap implementation The timely detection of lamivudine, adefovir, entecavir and telbivudine resistance, and the detection of hepatitis B virus and hepatitis C virus genotyping can reduce the incidence of nucleoside (acid) analogue resistance and improve the success rate of refractory hepatitis B. During antiviral therapy, some hepatocyte-protective treatments should be noted. Treatment of chronic viral hepatitis from antiviral drugs with different sites of action can be combined, which can obtain antiviral synergy, improve the antiviral effect and reduce the occurrence of drug resistance. High priority needs to be given to hepatitis B virus family aggregation and intervention, attention should be paid to hepatitis B virus/hepatitis C virus co-infection, chronic hepatitis B combined with fatty liver, the application of immunomodulatory therapy in chronic hepatitis B, the role of liver puncture in the diagnosis of chronic hepatitis B, and the determination of therapeutic efficacy. Through the new high-tech instrument flow cytometry integrating laser, electrophysics, photoelectric measurement, computer, cell fluorescence chemistry and monoclonal antibody technology for cellular immune function determination (CD3, CD4, CD8, CD80, CD86, etc.), the immune function status of patients can be clarified, which is beneficial to the diagnosis and treatment of liver disease, the evaluation of patients’ condition and the use of antiviral therapy drugs It has good reference value for the evaluation of patients’ condition and the use of antiviral therapy drugs.